Synaptogenix Inc (SNPX)

[InTheTrenches]

Nice to be recognized as the only company showing signs of life in Alzheimer's in this recent Seeking Alpha article.

https://seekingalpha.com/article/4251846-nanostring-technologies-fundraising-signals-inflection-point-strategy

There is a virtual graveyard in AD with only one company showing any sign of life. Neurotrope (NTRP) is the last company standing in AD with a highly anticipated readout in the summer of 2019. NTRP actually showed an improvement in Severe Impairment Battery (SIB) in a subset of patients that didn't take Memantine.

All AD trials measure the rate of decline in SIB, so for even a subset of patients in a clinical trial to show an increase is quite exceptional. NTRP uses a different target than plaque, the big pharmas' focus. Many trials involving amyloid plaque have failed. Any big pharma will need to play catch up and fast to stay in the race for AD therapy.

The author is somewhat correct. We do target other aspects of Alzheimer's--synaptic regrowth, neuronal protection, blood brain barrier integrity, etc. But we DO target amyloid plaque in addition to these other symptoms.

Multi-modal.